Project Relax-AHF-EU – A multicenter, prospective, randomized, open label study to assess the effect of serelaxin versus…

Basic data

Acronym:
Relax-AHF-EU
Title:
A multicenter, prospective, randomized, open label study to assess the effect of serelaxin versus standard of care in acute heart faiure (AHF) patients
Duration:
16/09/2016 to 18/09/2017
Abstract / short description:
The aim of this study is to assess the efficacy, safety and tolerability of intravenous infusion of 30 µg/kg/day serelaxin administered for 48 hours when added to standard therapy in patients hospitalized for acute heart failure. Efficacy will be determined based on the combined primary endpoint of in-hospital worsening of heart failure requiring rescue therapy and all-cause death through day 5. Patients will be followed-up for 30 days.

The aim of this study is to generate clinical evidence, especially on the short-term period (in-hospital and at 30 days) that wil complement existing and fututre serelaxin data sets in AHF.
Keywords:
cardiovascular disease
Herzkreislauferkrankungen
Acute Heart Failure
Akute Herzinsuffizienz
Zusatztherapie (additional therapy)

Involved staff

Managers

Department of Internal Medicine
Hospitals and clinical institutes, Faculty of Medicine

Local organizational units

Department of Internal Medicine
Hospitals and clinical institutes
Faculty of Medicine

Funders

Nürnberg, Bayern, Germany
Help

will be deleted permanently. This cannot be undone.